BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10480430)

  • 21. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
    Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
    Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
    Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
    Winter SS; Greene JM; McConnell TS; Willman CL
    Leukemia; 1999 Dec; 13(12):2007-11. PubMed ID: 10602422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
    Khazaal MS; Hamdan FB; Al-Mayah QS
    Mol Genet Genomic Med; 2019 Aug; 7(8):e809. PubMed ID: 31206255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
    Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
    Tbakhi A; Pettay J; Sreenan JJ; Abdel-Razeq H; Kalaycio M; Hoeltge G; Miller ML; Tubbs RR
    Am J Clin Pathol; 1998 Jan; 109(1):16-23. PubMed ID: 9426513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of the cell cycle, differentiation and irradiation on the nuclear location of the abl, bcr and c-myc genes in human leukemic cells.
    Bártová E; Kozubek S; Kozubek M; Jirsová P; Lukásová E; Skalníková M; Buchnícková K
    Leuk Res; 2000 Mar; 24(3):233-41. PubMed ID: 10739005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia.
    Barnes DJ; Melo JV
    Acta Haematol; 2002; 108(4):180-202. PubMed ID: 12432215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
    Peng C; Chen Y; Yang Z; Zhang H; Osterby L; Rosmarin AG; Li S
    Blood; 2010 Jan; 115(3):626-35. PubMed ID: 19965668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
    Andersson BS; Collins VP; Kurzrock R; Larkin DW; Childs C; Ost A; Cork A; Trujillo JM; Freireich EJ; Siciliano MJ
    Leukemia; 1995 Dec; 9(12):2100-8. PubMed ID: 8609723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
    Suh SP; Kee SJ; Lim WH; Song JW; Lee SK; Kim JP; Shin JH; Ryang DW
    Clin Chem Lab Med; 2000 Sep; 38(9):939-44. PubMed ID: 11097354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
    Gaiger A; Henn T; Hörth E; Geissler K; Mitterbauer G; Maier-Dobersberger T; Greinix H; Mannhalter C; Haas OA; Lechner K; Lion T
    Blood; 1995 Sep; 86(6):2371-8. PubMed ID: 7662984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph negative chronic myeloid leukemia.
    Michalová K; Zemanová Z; Bkezinová J; Moravcová J; Oltová A; Sobotka J; Kuglík P; Kozak T; Sindelarová L; Jankovská M; Obomilová A; Sieglová Z; Polák J; Nádvorníková S; Haskovec C
    Leuk Lymphoma; 2002 Aug; 43(8):1695-700. PubMed ID: 12400616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
    Sharma P; Kumar L; Mohanty S; Kochupillai V
    Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
    Mundhada S; Luthra R; Cano P
    BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
    Vieira SA; Deininger MW; Sorour A; Sinclair P; Foroni L; Goldman JM; Melo JV
    Genes Chromosomes Cancer; 2001 Dec; 32(4):353-63. PubMed ID: 11746976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.